1. Home
  2. SG vs ASMB Comparison

SG vs ASMB Comparison

Compare SG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$6.89

Market Cap

635.7M

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$34.75

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
ASMB
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
635.7M
553.6M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
SG
ASMB
Price
$6.89
$34.75
Analyst Decision
Hold
Strong Buy
Analyst Count
15
6
Target Price
$15.54
$43.40
AVG Volume (30 Days)
4.3M
115.0K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$685,184,000.00
$37,191,000.00
Revenue This Year
$4.14
$42.01
Revenue Next Year
$11.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.43
31.30
52 Week Low
$5.14
$7.75
52 Week High
$35.95
$39.71

Technical Indicators

Market Signals
Indicator
SG
ASMB
Relative Strength Index (RSI) 50.33 52.92
Support Level $6.59 $32.25
Resistance Level $7.48 $36.92
Average True Range (ATR) 0.40 1.68
MACD 0.03 -0.47
Stochastic Oscillator 40.45 41.71

Price Performance

Historical Comparison
SG
ASMB

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: